Domino, ME, Swartz, MS. Who are the new users of antipsychotic medications?
2008; 59: 507–14.
Dabelea, D. The accelerating epidemic of childhood diabetes. Lancet
2009; 373: 1999–2000.
Mukherjee, S, Decina, P, Bocola, V, Saraceni, F, Scapicchio, PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry
1996; 37: 68–73.
Dixon, L, Weiden, P, Delahanty, J, Goldberg, R, Postrado, L, Lucksted, A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull
2000; 26: 903–12.
Regenold, WT, Thapar, RK, Marano, C, Gavirneni, S, Kondapavuluru, PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord
2002; 70: 19–26.
Buse, JB, Cavazzoni, P, Hornbuckle, K, Hutchins, D, Breier, A, Jovanovic, L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol
2003; 56: 164–70.
Ramaswamy, K, Masand, PS, Nasrallah, HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry
2006; 18: 183–94.
Smith, M, Hopkins, D, Peveler, RC, Holt, RIG, Woodward, M, Ismail, K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry
2008; 192: 406–11.
Saddichha, S, Manjunatha, N, Ameen, S, Akhtar, S. Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand
2008; 117: 342–7.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Malig, C. The Civil Registration System in Denmark. Technical Paper No 66. International Institute for Vital Registration and Statistics, 1996.
Juel, K, Helweg-Larsen, K. The Danish registers of causes of death. Dan Med Bull
1999; 46: 354–7.
Andersen, TF, Madsen, M, Jorgensen, J, Mellemkjaer, L, Olsen, JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull
1999; 46: 263–8.
Munk-Jorgensen, P, Mortensen, PB. The Danish Psychiatric Central Register. Dan Med Bull
1997; 44: 82–4.
WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. WHO Collaborating Centre for Drug Statistics Methodology, 2003.
World Health Organization. Glossary of Mental Disorders and Guide to their Classification for Use in Conjunction with the International Classification of Diseases, 8th Revision. WHO, 1974.
World Health Organization. International Statistical Classification of Diseases and Health Related Problems, 10th revision [Danish version]. Munksgaard, 1993.
Gianfrancesco, FD, Grogg, AL, Mahmoud, RA, Wang, RH, Nasrallah, HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry
2002; 63: 920–30.
Gianfrancesco, F, Grogg, A, Mahmoud, R, Wang, RH, Meletiche, D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther
2003; 25: 1150–71.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry
2004; 65: 267–72.
Newcomer, JW, Nasrallah, HA, Loebel, AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol
2004; 24: S1–6.
Yood, MU, DeLorenze, G, Quesenberry, CP Jr, Oliveria, SA, Tsai, AL, Willey, VJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent–results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf
2009; 18: 791–9.
Kristensen, JK. Identification of the Type 2 Diabetes Population in a Danish County and Evaluation of the Performed Care in a Five-Year Period. Aarhus Universitet, 2000.
Drivsholm, TB, Frederiksen, K, de Fine, ON, Odegaard, B, Kristensen, JK. The prevalence of diabetes in Denmark. Development of a method for a registry-based assessment [in Danish]. Ugeskr Laeger
2003; 165: 2887–91.
Leslie, DL, Rosenheck, RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry
2004; 161: 1709–11.
Jin, H, Meyer, JM, Jeste, DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry
2002; 14: 59–64.
Centers for Disease Control and Prevention. National Diabetes Surveillance System. Centers for Disease Control and Prevention, 2009 (http://apps.nccd.cdc.gov/ddtstrs/).
Berger, B, Stenstrom, G, Sundkvist, G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diabetes Care
1999; 22: 773–8.
Ryan, R, Newnham, A, Khunti, K, Majeed, A. New cases of diabetes mellitus in England and Wales, 1994–1998: database study. Public Health
2005; 119: 892–9.
Garancini, MP, Gobbi, C, Errera, A, Sergi, A, Gallus, G. Age-specific incidence and duration of known diabetes. The Cremona Study. Diabetes Care
1996; 19: 1279–82.